IRMA(IMATINIB RESISTANCE MUTATION ANALYSIS)IN CML
This test is useful for detecting over 90 known and novel mutations in ABL kinase domain of Ph chromosome including T3151 and P-loop mutations responsible for resistance to Imatinib in CML patients. Imatinib is a Tyrosine kinase inhibitor (TKI) which helps in overcoming mutations to aid in the treatment of CML.
How to prepare for the test?
Submit latest BCR-ABL Quantitative report along with sample.